SB1713 expands the authority of Arizona pharmacists to independently provide certain point-of-care testing and treatment services under a statewide written protocol approved by the State Board of Pharmacy. The bill allows pharmacists to order, perform, and interpret FDA-authorized, CLIA-waived tests and to initiate treatment for eligible patients age 12 and older for influenza, group A strep pharyngitis, COVID-19 and other coronavirus respiratory illnesses, and other public-health-threat conditions identified by the Department of Health Services. It also authorizes pharmacists to initiate and dispense HIV preexposure prophylaxis (PrEP) and postexposure prophylaxis (PEP) under protocol.
The bill requires the board to create an advisory committee with pharmacists, physicians, a nurse practitioner, and a patient advocate to help develop and annually review the protocols. The protocols must address training, documentation, referrals, screening, exclusion criteria, follow-up care, and records retention. Pharmacists must use evidence-based guidelines, notify primary care providers in specified circumstances, maintain records, provide patient notices and privacy, carry professional liability insurance, and obtain parental consent for minors. The bill also prohibits pharmacists from independently initiating opioid treatment and makes clear that pharmacists are not required to provide these services.
The bill’s impact on state law is to create a new statutory framework in Title 32 for pharmacist-led testing and limited treatment, shifting some routine infectious-disease care from physician-only settings to pharmacies. It imposes new operational and compliance requirements on pharmacies and pharmacists, while also limiting liability for primary care providers and preserving patient referral pathways. In practice, it expands access to rapid testing and treatment, especially for common respiratory infections and HIV prevention, and it may affect pharmacy staffing, training, insurance, and privacy standards.
Overall sentiment appears mixed but generally supportive, with the bill advancing through both chambers and ultimately being signed into law. Committee and floor votes show meaningful support, though not unanimous, suggesting the measure was viewed as a practical access-to-care expansion but still raised concerns among some lawmakers. The lack of recorded transcript discussion limits detail, but the divided votes indicate some caution about scope, patient safety, and the role of pharmacists in independent clinical decision-making.
Notable points of contention likely centered on whether pharmacists should be allowed to diagnose and treat without physician oversight, how much clinical judgment can be delegated, and whether the safeguards in the statewide protocol are sufficient. Additional concerns may have involved treatment of minors, notification to primary care providers, liability exposure, and the expansion of pharmacist authority into HIV prophylaxis and other public-health-related treatments. Supporters likely emphasized access, convenience, and timely treatment, while critics likely focused on oversight, standards of care, and the boundaries of pharmacy practice.
SB1713 adds new sections to Arizona law governing the State Board of Pharmacy and expands pharmacist scope of practice to include independent CLIA-waived testing and limited treatment initiation under statewide protocols. It creates a new advisory committee, requires protocol development and annual review, and imposes requirements for training, documentation, referrals, patient consent, privacy, notice, and professional liability insurance. It also authorizes pharmacist initiation of PrEP and PEP and sets specific conditions for HIV-related services, while preserving referral obligations and limiting certain liabilities.
The bill appears to have had generally favorable momentum, passing committee and floor votes in both chambers and being signed into law, but not without opposition. The vote margins suggest support was substantial but not unanimous, indicating that lawmakers were divided over the appropriate extent of pharmacist authority and the adequacy of patient-safety safeguards. With no committee transcript available, the record mainly shows procedural advancement and some resistance rather than detailed public debate.
The main areas of contention are the expansion of pharmacist authority to independently test and treat patients, especially without physician oversight, and the adequacy of protocol-based safeguards. Likely concerns include clinical safety, treatment of minors, liability and referral responsibilities, and whether pharmacists should be allowed to initiate HIV PrEP/PEP and other treatments. Supporters likely framed the bill as improving access to care and reducing delays, while opponents likely worried about scope-of-practice expansion and continuity of care.